Akorn searches for new CEO after failed Fresenius mergerUS generics firm Akorn is searching for a new CEO in the wake of a failed merger with Share XAkorn searches for new CEO after failed Fresenius mergerhttps://pharmaphorum.com/news/akorn-searches-for-new-ceo-after-failed-fresenius-merger/
Shareholders approve Takeda’s $59bn takeover of ShireTakeda’s $59 billion acquisition of Shire has been backed by shareholders from both companies, clearing the way for Share XShareholders approve Takeda’s $59bn takeover of Shirehttps://pharmaphorum.com/news/shareholders-approve-takedas-59bn-takeover-of-shire/
Genentech buys NASH biotech JecureRoche’s Genentech unit has bought California biotech Jecure Therapeutics, which is researching drugs that could be used in Share XGenentech buys NASH biotech Jecurehttps://pharmaphorum.com/news/genentech-buys-nash-biotech-jecure/
Takeda must sell gastro drug to merge with Shire – EU regulatorsEuropean regulators have officially rubber stamped Takeda’s $62 billion takeover of Shire, although the merged company will have Share XTakeda must sell gastro drug to merge with Shire – EU regulatorshttps://pharmaphorum.com/news/takeda-must-sell-gastro-drug-to-merge-with-shire-eu-regulators/
AZ sells rights to RSV virus drug to Sobi for $1.5bnAstraZeneca has agreed to sell the rights to its drug Synagis (palivizumab) to Swedish Orphan Biovitrum (Sobi) for Share XAZ sells rights to RSV virus drug to Sobi for $1.5bnhttps://pharmaphorum.com/news/az-sells-rights-to-rsv-virus-drug-to-sobi-for-1-5bn/
Takeda hurries $62bn Shire acquisition, calls investor vote next monthTakeda will hold an investor vote on its $62 billion acquisition of Shire next month, and aims to Share XTakeda hurries $62bn Shire acquisition, calls investor vote next monthhttps://pharmaphorum.com/news/takeda-hurries-62bn-shire-acquisition-calls-investor-vote-next-month/
Takeda CEO confident about Shire mergerTakeda’s CEO has said he is confident that its $62 billion acquisition of Shire will go ahead, despite Share XTakeda CEO confident about Shire mergerhttps://pharmaphorum.com/news/takeda-ceo-confident-about-shire-merger/
Novartis to buy cancer drug firm Endocyte for $2.1bnNovartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash. The Swiss pharma giant Share XNovartis to buy cancer drug firm Endocyte for $2.1bnhttps://pharmaphorum.com/news/novartis-to-buy-cancer-drug-firm-endocyte-for-2-1bn/
Mundipharma buys Spanish biosimilars firm Cinfa BiotechMundipharma, a network of independent pharma companies, has bought Spanish biosimilars development company Cinfa Biotech. The deal will Share XMundipharma buys Spanish biosimilars firm Cinfa Biotechhttps://pharmaphorum.com/news/mundipharma-buys-spanish-biosimilars-firm-cinfa-biotech/
